Guidance

Influenza: treatment and prophylaxis using anti-viral agents

Guidance on how to manage influenza (flu) using anti-viral agents.

Documents

PHE guidance on use of antiviral agents for the treatment and prophylaxis of influenza

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (eg a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

The use of antivirals for the treatment and prophylaxis of influenza: summary of guidance for healthcare professionals

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (eg a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Letter to clinicians regarding the use of antivirals in influenza

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (eg a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Detail

This guidance covers:

  • definitions
  • treatment of suspected or confirmed influenza
  • post-exposure prophylaxis supply of zanamivir acqueous solution
  • use of anti-virals in pregnancy, breastfeeding, hepatic or renal dysfunction

The changes to 2016-17 guidance are:

  • improved layout and readability
  • removal of links to withdrawn and expired documents
  • updated content in section 1.3.4 “Unlicensed treatments”
  • updated appendices including a new summary algorithm for prescribing antivirals in Appendix 2 and the process for requesting zanamivir aqueous solution
  • a new “frequently asked questions” section at the end of the guidance